Deletion of 3p13 is a late event linked to progression of : fusion prostate cancer.

Introduction: Deletion of 3p13 is one of the most common alterations in prostate cancer preferentially occurring in tumors with fusion. The cause for the striking association between 3p13 loss and fusion is unknown.

Methods: Here, we made use of a preexisting heterogeneity prostate cancer tissue microarray including ten tissue spots from ten different tumor areas of 317 cancers to examine the spatial distribution of 3p13 deletions (determined by fluorescence in situ hybridization) in prostate cancer areas with and without ERG overexpression (determined by immunohistochemistry).

Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer.

Background: Animal model experiments have suggested a role of the DNA repair protein ERCC1 (Excision Repair Cross-Complementation Group 1) in prostate cancer progression.

Methods: To better understand the impact of ERCC1 protein expression in human prostate cancer, a preexisting tissue microarray (TMA) containing more than 12,000 prostate cancer specimens was analyzed by immunohistochemistry and data were compared with tumor phenotype, PSA recurrence and several of the most common genomic alterations (TMPRSS2:ERG fusions: deletions of PTEN, 6q, 5q, 3p).

Results: ERCC1 staining was seen in 64.